Company Overview
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 17.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 22.4%.
Net profit has compounded at 32.5% per year over the last five years.
Revenue has grown at a 22.4% CAGR over the past five years.
Trades at a P/E of 33.3, below the sector median of 40.0.
Maintains a net profit margin of 25.3%.
Recent Developments
- Mar 2026 Revenue of ₹827.88 Cr (+18.9% YoY); net profit ₹209.12 Cr.
- Trailing 12 Months Year-on-year growth — revenue +18.9%, earnings +11.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.4%, profit CAGR 32.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.44% |
| 1 Year: | 18.86% |
Compounded Profit Growth
| 5 Years: | 32.52% |
| 1 Year: | 11.26% |
Stock Price Performance
| 1 Year: | +25.06% |
| 6 Months: | +17.54% |
| 3 Months: | +35.61% |
| 1 Month: | -8.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.14 · Neutral
P/E of 33.33 is below the sector median of 39.97 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 22.4%.
- Excellent profit margin of 25.3%.
- Compounding revenue at 22.4% over 5 years.
- Profit CAGR of 32.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SUPRIYA Supriya Lifescience Limited NSEPHARMA | 865.90 | 33.33 | ₹6,969.01 Cr | 0.12% | 22.38% | 17.46% | 22.44% | 32.52% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 184.11 Cr | 145.07 Cr | 199.83 Cr | 206.44 Cr | 276.53 Cr |
| Cost of Revenue | 54.83 Cr | 31.77 Cr | 55.73 Cr | 61.20 Cr | 105.33 Cr |
| Gross Profit | 129.28 Cr | 113.30 Cr | 144.10 Cr | 145.24 Cr | 171.20 Cr |
| Operating Expenses | 67.78 Cr | 68.05 Cr | 78.09 Cr | 79.98 Cr | 82.08 Cr |
| Operating Income | 61.50 Cr | 45.25 Cr | 66.01 Cr | 65.26 Cr | 89.12 Cr |
| EBITDA | 70.56 Cr | 54.38 Cr | 75.37 Cr | 74.23 Cr | 101.09 Cr |
| Interest Expense | 41.70 L | 51.20 L | 41.50 L | 49.40 L | 46.80 L |
| Pretax Income | 64.06 Cr | 47.41 Cr | 68.32 Cr | 66.92 Cr | 92.13 Cr |
| Tax Provision | 13.68 Cr | 12.62 Cr | 17.89 Cr | 17.25 Cr | 17.90 Cr |
| Net Income | 50.38 Cr | 34.79 Cr | 50.43 Cr | 49.67 Cr | 74.23 Cr |
| Diluted EPS | 6.29 | 4.32 | 6.27 | 6.17 | 9.22 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 451.01 Cr | 557.41 Cr | 696.49 Cr | 827.88 Cr |
| Cost of Revenue | - | 230.55 Cr | 278.49 Cr | 211.18 Cr | 254.03 Cr |
| Gross Profit | - | 220.46 Cr | 278.92 Cr | 485.31 Cr | 573.85 Cr |
| Operating Expenses | - | 105.14 Cr | 121.17 Cr | 244.96 Cr | 308.21 Cr |
| Operating Income | - | 115.32 Cr | 157.75 Cr | 240.35 Cr | 265.64 Cr |
| EBITDA | - | 136.98 Cr | 185.20 Cr | 270.59 Cr | 305.08 Cr |
| Interest Expense | - | 1.68 Cr | 3.70 Cr | 1.67 Cr | 1.89 Cr |
| Pretax Income | - | 123.49 Cr | 165.69 Cr | 248.48 Cr | 274.78 Cr |
| Tax Provision | - | 33.63 Cr | 46.58 Cr | 60.52 Cr | 65.66 Cr |
| Net Income | - | 89.86 Cr | 119.11 Cr | 187.96 Cr | 209.12 Cr |
| Diluted EPS | - | 11.16 | 14.80 | 23.35 | 25.98 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 820.28 Cr | 921.45 Cr | 1,112.31 Cr | 1,357.11 Cr |
| Current Assets | - | 464.89 Cr | 398.01 Cr | 437.04 Cr | 532.30 Cr |
| Cash & Equivalents | - | 85.25 Cr | 68.35 Cr | 76.00 Cr | 37.55 Cr |
| Inventory | - | 115.77 Cr | 85.25 Cr | 118.35 Cr | 159.60 Cr |
| Receivables | - | 84.66 Cr | 111.68 Cr | 134.36 Cr | 219.45 Cr |
| Total Liabilities | - | 120.82 Cr | 106.08 Cr | 115.55 Cr | 159.37 Cr |
| Current Liabilities | - | 95.78 Cr | 77.11 Cr | 82.16 Cr | 121.04 Cr |
| Long Term Debt | 0 | 0 | 0 | 0 | - |
| Total Debt | - | 22.47 Cr | 5.49 Cr | 5.38 Cr | 5.43 Cr |
| Total Equity | - | 699.46 Cr | 815.37 Cr | 996.76 Cr | 1,197.73 Cr |
| Shares Outstanding | - | 8.05 Cr | 8.05 Cr | 8.05 Cr | 8.05 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 63.60 Cr | 113.31 Cr | 164.68 Cr | 185.77 Cr |
| Investing Cash Flow | - | -123.65 Cr | -173.57 Cr | -152.24 Cr | -176.17 Cr |
| Financing Cash Flow | - | -10.28 Cr | -22.36 Cr | -8.23 Cr | -9.88 Cr |
| Capital Expenditure | - | -107.91 Cr | -145.66 Cr | -162.38 Cr | -152.24 Cr |
| Free Cash Flow | - | -44.30 Cr | -32.35 Cr | 2.30 Cr | 33.53 Cr |
| Net Change in Cash | - | -70.33 Cr | -82.63 Cr | 4.20 Cr | -28.70 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 48.9% | 50.0% | 69.7% | 69.3% |
| Operating Margin % | - | 25.6% | 28.3% | 34.5% | 32.1% |
| Net Margin % | - | 19.9% | 21.4% | 27.0% | 25.3% |
| ROE % | - | 12.8% | 14.6% | 18.9% | 17.5% |
| ROCE % | - | 15.9% | 18.7% | 23.3% | 21.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SUPRIYA
SUPRIYA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9YUjBpUDFqeHN0Sjh6LXpCSnBoaUhvN0pEcDNJYVF6Vnhqb1F5V2lPZlc3RmNRb0FtbUZOemZBRHdRZ2xYQ3lqVDRLMmM2WnVxZ0Y1V2lBcHYwbVVnNDFQVEpmY2U1MWtvQjFwaXI4YlZvUDZnZFFYUWdn?oc=5" target="_blank">SUP…
Supriya Lifescience tanks 12%; what's ailing this pharma stock? - Business Standard
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZEhIWE1ZcFVVbjBUV1ByVldFSkxUcDB1VUUzQjc5YmV4RFh3YXNqRVFwbXJLQlg3ZEJkWERHY1NBMWw2cU1zOFM4OXF1ZXJNNE5UQUFtQkhoNDA2dF9VVTVIN2hiZnBBSkhkSklVdDdnMEZGSVp0ckI0WHJrXzRENEZSS1pWTGJVemxWT3…
Stocks to Watch Today: Supriya Lifescience, Rubicon Research, Fortis Healthcare, Fermenta Biotech - BusinessLine
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxOYlpYMVdEQlZocy1GLUpxa2E1ZnBuSlJna2ZJbWJTVFNRdTM1a2lFYm9QSzdxZEF3UnluRUNwYUREYTVvaUowY3hveEc3clotal9MSjhGVV9uUlhJeHhkMkJOcXdtTldFeU5ldVZiYUFMbnRjUEZKSlhaUEhBekJKa2hiaW9DdHB3ek1VTH…
Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoY - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPbm0zRl82T0Q4aTVWZnM1b00yMHdTaGYtVy1fdzFJdjh3dnBKX1ZyaUJtQUVpLTZqNUU1OXdPMW1MMktxX1JTM0dpSzZLaVp2dDNRa3o4cFMtWWxJS3c3TVN0TDRsR1NXazhwdDlLWWE4emhtaDRJNnlNYlpjZEs4b1ZZazNrYmdCMmt6Nl…
Supriya Lifescience promoters report no share encumbrance in FY26 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZElmQkdRMExfQ1VoZ1RwZ2hKMzV1a1dLM0tmOXE0cHZTUHNwcFliQVZlMGZMcnJjbFM0SFpySV9WUmZjZmJsT2RPXzZWTVNRUXZXLVJGa0htMFFqODE5TXdTVXBPTXBYY3N3eUhrekpNVG9VUW5BaGhpRW1qN0VqUXFBWXRQRHJMNFNJaz…
With EPS Growth And More, Supriya Lifescience (NSE:SUPRIYA) Makes An Interesting Case - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQSkdqZGZ4bWR0dGhybjA5V2tVMmdBVHA1dDFIaXczZ19FYkI0S3lPVVY1aGh2X21EWTlDd3llMHdKYVJ3UmNEV0Z0MVNsVlVlNTNETzItQVRjYnplbzdOTW54SkRNc0MtanJyRnd1c2lPSF9CQktFbXhtWFpOZ3dkbThwd0xxUTg3LV9sV1…
SUPRIYA — Frequently Asked Questions
What is the current share price of Supriya Lifescience Limited (SUPRIYA)?
As of 2026-07-15 09:52 IST, Supriya Lifescience Limited (SUPRIYA) trades at ₹865.90 on NSE. Its 52-week range is ₹553.35 to ₹1,052.50.
What is the market capitalisation of SUPRIYA?
Supriya Lifescience Limited (SUPRIYA) has a market capitalisation of ₹6,969.01 Cr on NSE.
What is the P/E ratio of SUPRIYA?
SUPRIYA trades at a trailing price-to-earnings (P/E) ratio of 33.33. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.68.
Does SUPRIYA pay a dividend?
Supriya Lifescience Limited (SUPRIYA) currently offers a dividend yield of 0.12%.
What is the return on equity (ROE) of SUPRIYA?
SUPRIYA has a return on equity (ROE) of 17.46%. Its return on capital employed (ROCE) is 22.38%.
Is SUPRIYA a good stock to buy?
This page provides a data-driven analysis of Supriya Lifescience Limited (SUPRIYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.